We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.56 | -13.2163138875 | 19.37 | 19.7 | 15.8401 | 35254 | 17.3404564 | CS |
4 | -3.91 | -18.8706563707 | 20.72 | 24.11 | 15.8401 | 52404 | 19.89195821 | CS |
12 | -6.69 | -28.4680851064 | 23.5 | 26.565 | 15.8401 | 64385 | 21.65884111 | CS |
26 | -10.06 | -37.4395236323 | 26.87 | 33 | 15.8401 | 121207 | 25.53637875 | CS |
52 | 8.28 | 97.0691676436 | 8.53 | 33 | 8.2 | 88006 | 22.88046034 | CS |
156 | -3.62 | -17.7190406265 | 20.43 | 33 | 1.77 | 217980 | 12.18855739 | CS |
260 | -8.19 | -32.76 | 25 | 42.86 | 1.77 | 205339 | 12.96801315 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions